Thrombolex, Inc. Announces the New Bashir™ .035 Endovascular Catheters
Thrombolex, Inc., announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™ S-B .035 Endovascular Catheters, which are comparable with an 0.035” guidewire. The BASHIR™ and BASHIR™ S-B Endovascular Catheters are 510(k) cleared for the treatment of acute pulmonary embolism (PE).
New Britain, PA, January 09, 2024 --(PR.com)-- Thrombolex, Inc., a medical device company that develops innovative devices for the treatment of arterial and venous thromboembolic diseases, announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™ S-B .035 Endovascular Catheters, which are comparable with an 0.035” guidewire. The BASHIR™ and BASHIR™ S-B Endovascular Catheters are 510(k) cleared for the treatment of acute pulmonary embolism (PE). This FDA clearance was based upon the positive results from the pivotal RESCUE Study, which was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Grant # R44HL151032-03) and the Commonwealth of Pennsylvania’s Department of Health.
The BASHIR™ catheters resolve thrombus through pharmacomechanical lysis (PML). Targeted thrombolysis are delivered from the expandable infusion basket directly into the clot enabling the immediate restoration of blood flow and optimal resolution of thrombus. This results in a highly effective treatment with ease of placement, shorter procedure time, and superior safety.
Dr. Triston Smith and Dr. Gregory Suero, Interventitional Cardiologists (Trinity Medical Center West, Steubenville, Ohio), said, “Catheter-based pulmonary embolism management should be simple, safe, and effective. The BASHIR™ Endovascular Catheter, with its unique and innovative design, exceeds expectations in those three categories. The 0.035” wire compatibility simplifies the procedure even more and places the BASHIR™ Endovascular Catheter as the premier catheter for the management of this patient population.”
The BASHIR™ Catheters are now available in 7F and 8F sizes. For further information or to schedule a representative visit, please contact Customer Service at 844.792.6300.
About Thrombolex, Inc.
Founded in 2016, Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmacomechanical lysis (PML) in patients who suffer from arterial and venous thromboembolic conditions. The Company is currently marketng eight (8) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platorm technology.
For More Information
Please contact Tony Litwiller, Chief Commercial Officer at Tony.L@thrombolex.com or visit our website www.thrombolex.com.
The BASHIR™ catheters resolve thrombus through pharmacomechanical lysis (PML). Targeted thrombolysis are delivered from the expandable infusion basket directly into the clot enabling the immediate restoration of blood flow and optimal resolution of thrombus. This results in a highly effective treatment with ease of placement, shorter procedure time, and superior safety.
Dr. Triston Smith and Dr. Gregory Suero, Interventitional Cardiologists (Trinity Medical Center West, Steubenville, Ohio), said, “Catheter-based pulmonary embolism management should be simple, safe, and effective. The BASHIR™ Endovascular Catheter, with its unique and innovative design, exceeds expectations in those three categories. The 0.035” wire compatibility simplifies the procedure even more and places the BASHIR™ Endovascular Catheter as the premier catheter for the management of this patient population.”
The BASHIR™ Catheters are now available in 7F and 8F sizes. For further information or to schedule a representative visit, please contact Customer Service at 844.792.6300.
About Thrombolex, Inc.
Founded in 2016, Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmacomechanical lysis (PML) in patients who suffer from arterial and venous thromboembolic conditions. The Company is currently marketng eight (8) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platorm technology.
For More Information
Please contact Tony Litwiller, Chief Commercial Officer at Tony.L@thrombolex.com or visit our website www.thrombolex.com.
Contact
Thrombolex, Inc.
Tony Litwiller
(704) 408-0927
www.Thrombolex.com
Tony Litwiller
(704) 408-0927
www.Thrombolex.com
Contact
Multimedia
Categories